Nicholas J Wang
Overview
Explore the profile of Nicholas J Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
2738
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin C, Vennam S, Purington N, Lin E, Varma S, Han S, et al.
Breast Cancer Res Treat
. 2019 Aug;
178(2):307-316.
PMID: 31420779
Purpose: The detection rate of breast ductal carcinoma in situ (DCIS) has increased significantly, raising the concern that DCIS is overdiagnosed and overtreated. Therefore, there is an unmet clinical need...
2.
Risom T, Langer E, Chapman M, Rantala J, Fields A, Boniface C, et al.
Nat Commun
. 2018 Sep;
9(1):3815.
PMID: 30232459
Intratumoral heterogeneity in cancers arises from genomic instability and epigenomic plasticity and is associated with resistance to cytotoxic and targeted therapies. We show here that cell-state heterogeneity, defined by differentiation-state...
3.
King C, Woodward J, Schwartzman J, Coleman D, Lisac R, Wang N, et al.
Oncotarget
. 2018 Jan;
8(67):111084-111095.
PMID: 29340039
Recent work demonstrates that castration-resistant prostate cancer (CRPC) tumors harbor countless genomic aberrations that control many hallmarks of cancer. While some specific mutations in CRPC may be actionable, many others...
4.
Hafner M, Heiser L, Williams E, Niepel M, Wang N, Korkola J, et al.
Sci Data
. 2017 Nov;
4:170166.
PMID: 29112189
Traditional means for scoring the effects of anti-cancer drugs on the growth and survival of cell lines is based on relative cell number in drug-treated and control samples and is...
5.
Korkola J, Collisson E, Heiser L, Oates C, Bayani N, Itani S, et al.
PLoS One
. 2017 Oct;
12(10):e0186551.
PMID: 29020035
[This corrects the article DOI: 10.1371/journal.pone.0133219.].
6.
Hu Z, Mao J, Curtis C, Huang G, Gu S, Heiser L, et al.
Breast Cancer Res
. 2017 Feb;
19(1):17.
PMID: 28183333
No abstract available.
7.
Hu Z, Mao J, Curtis C, Huang G, Gu S, Heiser L, et al.
Breast Cancer Res
. 2016 Jul;
18(1):70.
PMID: 27368372
Background: High mitotic activity is associated with the genesis and progression of many cancers. Small molecule inhibitors of mitotic apparatus proteins are now being developed and evaluated clinically as anticancer...
8.
Coleman D, Van Hook K, King C, Schwartzman J, Lisac R, Urrutia J, et al.
Oncotarget
. 2016 Jun;
7(26):40690-40703.
PMID: 27276681
Prostate cancer is the most commonly diagnosed and second-most lethal cancer among men in the United States. The vast majority of prostate cancer deaths are due to castration-resistant prostate cancer...
9.
Fei S, Mitchell A, Heskett M, Vocke C, Ricketts C, Peto M, et al.
Nat Commun
. 2016 May;
7:11588.
PMID: 27174753
Cancer development is presumed to be an evolutionary process that is influenced by genetic background and environment. In laboratory animals, genetics and environment are variables that can largely be held...
10.
Fleyshman D, Cheney P, Strose A, Mudambi S, Safina A, Commane M, et al.
Cell Cycle
. 2015 Dec;
15(3):455-70.
PMID: 26694952
The realization, that the androgen receptor (AR) is essential for prostate cancer (PC) even after relapse following androgen deprivation therapy motivated the search for novel types of AR inhibitors. We...